Swedish Orphan Biovitrum

Historical price data

Sobi is a premier rare disease company with a mission to pioneer and deliver life-changing therapies for underserved patient populations. The company has established a strong commercial foundation with marketed products in hematology and immunology, complemented by a diversified pipeline of biologics and small molecules. Its strategy hinges on expanding global access, advancing high-potential clinical programs, and maintaining operational excellence to drive sustainable growth and leadership in the rare disease space.

Sobi employs a diversified, modality-agnostic platform encompassing recombinant proteins, monoclonal antibodies, small molecules, and advanced biologics, supported by integrated in-house manufacturing and development capabilities.

Sobi competes with large pharma (e.g., Sanofi, Roche, Takeda) in hematology and immunology, where differentiation is based on product profile, real-world evidence, and patient services. Its integrated model provides an advantage over pure-play biotechs but requires continuous innovation to defend against new modalities and competitors.